Skip to main content
AmigoFish

Jefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA

From BiotechTV - News · · 16 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.

Back to BiotechTV - News · Report a problem